In amblyopic children, digital therapeutic improves Visual a
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Researchers evaluated the efficacy and adherence of Luminopia One—a dichoptic treatment that applies therapeutic modifications to streaming content chosen by the patient. The effectiveness of amblyopia therapy can be limited by poor adherence. Dichoptic therapies are a new approach, but recent trials have demonstrated difficulty maintaining high adherence over extended periods of at-home treatment.

This single-arm, multicenter prospective pilot study enrolled children aged 4-12 with anisometropic, strabismic, or mixed amblyopia. The therapeutic was prescribed for 1 hour/day, 6 days/week for 12 weeks of at-home use. The primary endpoint was best-corrected visual acuity (BCVA) at the 12-week follow-up visit.

Results:
--In total, 90 participants (mean age, 6.7 ± 2.0 years) were enrolled, and 73/90 participants had prior treatment beyond refractive correction.

--For those who completed the 12-week visit, mean amblyopic eye BCVA improved from 0.50 logMAR to 0.35 logMAR (1.5 logMAR lines).

--Mean stereoacuity improved by 0.28 log arcsec. Median adherence was 86% (interquartile range, 70%-97%).

In this cohort, adherence was strong over the 12-week study period, and participants improved their visual acuity and stereoacuity in clinically and statistically important ways.

Source: https://www.jaapos.org/article/S1091-8531(21)00091-4/fulltext?rss=yes
Like
Comment
Share